scholarly journals Moving Average Based Index for Judging the Peak of the COVID-19 Epidemic

Author(s):  
Yunting He ◽  
Xiaojin Wang ◽  
Hao He ◽  
Jing Zhai ◽  
Bingshun Wang

A pneumonia outbreak caused by a novel coronavirus (COVID-19) has spread around the world. A total of 2,314,621 laboratory-confirmed cases, including 157,847 deaths (6.8%) were reported globally by 20 April 2020. Common symptoms of COVID-19 pneumonia include fever, fatigue, and dry cough. Faced with such a sudden outbreak of emerging infectious disease, traditional models for predicting the peak of the epidemic often show inconsistent results. With the aim to timely judge the epidemic peak and provide support for decisions for resuming production and returning to normal life based on publicly reported data, we used a seven-day moving average of log-transformed daily new cases (LMA) to establish a new index named the “epidemic evaluation index” (EEI). We used SARS epidemic data from Hong Kong to verify the practicability of the new index, and then applied it to the COVID-19 epidemic analysis. The results showed that the epidemic peaked, respectively, on 9 February and 5 February 2020, in Hubei Province and other provinces in China. The proposed index can be applied for judging the epidemic peak. While the global COVID-19 epidemic reached its peak in the middle of April, the epidemic peaks in some countries have not yet appeared. Global and united efforts are still needed to eventually eliminate the epidemic.

Author(s):  
Ghotekar D S ◽  
Vishal N Kushare ◽  
Sagar V Ghotekar

Coronaviruses are a family of viruses that cause illness such as respiratory diseases or gastrointestinal diseases. Respiratory diseases can range from the common cold to more severe diseases. A novel coronavirus outbreak was first documented in Wuhan, Hubei Province, China in December 2019. The World Health Organization (WHO) has declared the coronavirus disease 2019 (COVID-19) a pandemic. A global coordinated effort is needed to stop the further spread of the virus. A novel coronavirus (nCoV) is a new strain that has not been identified in humans previously. Once scientists determine exactly what coronavirus it is, they give it a name (as in the case of COVID-19, the virus causing it is SARS-CoV-2).


PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9725 ◽  
Author(s):  
Tingting Hu ◽  
Ying Liu ◽  
Mingyi Zhao ◽  
Quan Zhuang ◽  
Linyong Xu ◽  
...  

In mid-December 2019, a novel atypical pneumonia broke out in Wuhan, Hubei Province, China and was caused by a newly identified coronavirus, initially termed 2019 Novel Coronavirus and subsequently severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of 19 May 2020, a total of 4,731,458 individuals were reported as infected with SARS-CoV-2 among 213 countries, areas or territories with recorded cases, and the overall case-fatality rate was 6.6% (316,169 deaths among 4,731,458 recorded cases), according to the World Health Organization. Studies have shown that SARS-CoV-2 is notably similar to (severe acute respiratory syndrome coronavirus) SARS-CoV that emerged in 2002–2003 and Middle East respiratory syndrome coronavirus (MERS-CoV) that spread during 2012, and these viruses all contributed to global pandemics. The ability of SARS-CoV-2 to rapidly spread a pneumonia-like disease from Hubei Province, China, throughout the world has provoked widespread concern. The main symptoms of coronavirus disease 2019 (COVID-19) include fever, cough, myalgia, fatigue and lower respiratory signs. At present, nucleic acid tests are widely recommended as the optimal method for detecting SARS-CoV-2. However, obstacles remain, including the global shortage of testing kits and the presentation of false negatives. Experts suggest that almost everyone in China is susceptible to SARS-CoV-2 infection, and to date, there are no effective treatments. In light of the references published, this review demonstrates the biological features, spread, diagnosis and treatment of SARS-CoV-2 as a whole and aims to analyse the similarities and differences among SARS-CoV-2, SARS-CoV and MERS-CoV to provide new ideas and suggestions for prevention, diagnosis and clinical treatment.


2020 ◽  
Author(s):  
Dhruv Kumar

In December 2019, outbreak of novel coronavirus (COVID-19) occurred in Wuhan, Hubei Province, China and exported across the world leading to thousands of deaths and millions of suspected cases. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection into the host undergoes a huge number of complex replicative machineries which still remains unclear. Understanding the mechanism (s) of replication and mode of infection of SARS-CoV2 to human cells will help us in the development of novel vaccines or drugs for the eradication and prevention of the disease. This review compiles the knowledge of SARS-CoV2 replicative machinery, mode of infection to the human cells and the development of drugs and vaccines which are currently under clinical trials.


2020 ◽  
Vol 9 (4) ◽  
pp. 1578-1582

Nanotechnology is useful for many applications. The use of nanomaterials can help create new innovations that can be applied in several aspects, including medical aspects. In medicine, nanomedicine is the specific branch of nanoscience. Applied nanomedicine is useful for diagnosis, treatment, and prevention of medical disorders. The applied nanomedicine for diagnosis, nanodiagnosis, is confirmed for its advantage. In the present day, COVID-19 is a newly emerging infectious disease that already causes pandemic worldwide. This new emerging respiratory viral infection caused the pandemic and affected more than 17 million of the world population and result in many deaths. The diagnosis of this new disease is a big challenge in medicine. Of several new attempts in diagnosis, nanotechnology is presently applied for diagnostic purposes in managing COVID-19. The applied nanodiagnosis for managing COVID-19 is an interest application of nanotechnology. In this short review, the authors discuss the applied nanodiagnosis for COVID-19.


2020 ◽  
Author(s):  
Divyansh Sehgal

As humans are spreading throughout the world, infectious diseases have been a constant companion such as Bubonic Plague (200 Million deaths), 17th Century Great Plague (3 Million deaths), Plague of Justinian (30-50 Million deaths), etc . Coronavirus Disease (COVID-19) which was published on 11th January 2020 showing the intensity of Global research and development activity to develop a drug/vaccine against the disease. COVID-19 is an infectious disease caused by a newly discovered coronavirus. Human to human transmission has created a pandemic situation across the world. Pharmaceutical companies play a crucial role in this scenario to provide Drugs/Vaccines/Therapies to treat and tackle the novel coronavirus disease of 2019. This paper consists of the Drugs and Vaccines which are developed, or in the process of development , their current stage of development (clinical trials) with their patent review.


2021 ◽  
pp. 38-42
Author(s):  
Charles Haddad ◽  
Christopher Scuderi ◽  
Judelle Haddad-Lacle ◽  
Reetu Grewal ◽  
Jeffrey Jacqmein ◽  
...  

The world as we knew it changed at the beginning of 2020 with the explosion of the global pandemic caused by SARS-CoV-2, a.k.a. COVID-19. As of January 10, 2021, the novel coronavirus has infected over 89 million people worldwide and killed over 1.9 million. In the U.S., there have been 22 million people infected and 373,000 deaths. It has never been more important to protect our vulnerable patients and staff from infectious disease, especially during the time they spend in our offices and clinics. It quickly became apparent that there was a need for a dedicated location where patients could be seen that were too ill to be evaluated via telemedicine, but not ill enough to be sent to the Emergency Department (ED). To fill this need, our primary care network developed the Respiratory Evaluation Clinic (REC) concept. These were two geographical locations where the outlying clinics could send potentially infectious patients to evaluate and test COVID-19. Some recommendations, adaptations, lessons learned and the REC clinics' expansions to other locations throughout our network are discussed.


2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Giulio Viceconte ◽  
Nicola Petrosillo

There is an increasing concern about COVID-19 worldwide. This is a new emerging infectious disease caused by a novel coronavirus (SARS-CoV-2), which recently broke out from the Chinese city of Wuhan and has quickly spread in China, with sporadic cases in each continent [...].


2021 ◽  
Vol 96 (2) ◽  
pp. 143-146
Author(s):  
Jaeseok Park ◽  
Jaekwon Jung ◽  
Hyunsoo Kim ◽  
Changkeun Park ◽  
Daejin Kim ◽  
...  

On 11 February, 2020, the World Health Organization announced that COVID-19 was a novel coronavirus disease first detected in Wuhan, Hubei Province, China. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The complete clinical picture is not fully known. Illness ranges from mild to fatal. The common symptoms include fever, cough, and dyspnea usually developing 2-14 days after exposure. However, diarrhea was present in a few patients with COVID-19. We report a case of COVID-19 mimicking acute colitis.


2020 ◽  
Vol 2 (1) ◽  
pp. 01-11
Author(s):  
Bin Zhao

Background: An infectious disease caused by a novel coronavirus called COVID-19 has raged across the world since December 2019. The novel coronavirus first appeared in Wuhan, China, and quickly spread to Asia and now many countries around the world are affected by the epidemic. The deaths of many patients, including medical staff, caused social panic, media attention, and high attention from governments and world organizations. Today, with the joint efforts of the government, the doctors and all walks of life, the epidemic in Hubei Province has been brought under control, preventing its spread from affecting the lives of the people. Because of its rapid spread and serious consequences, this sudden novel coronary pneumonia epidemic has become an important social hot spot event. Through the analysis of the novel coronary pneumonia epidemic situation, we can also have a better understanding of sudden infectious diseases in the future, so that we can take more effective response measures, establish a truly predictable and provide reliable and sufficient information for prevention and control model. Methods: We establish different models according to the different developments of the epidemic situation, different time points, and different response measures taken by the government. To be specific, during the period of 2020.1.23-2020.2.7, the traditional SIR model is adopted; during the period of 2020.2.8-2020.3.30, according to the scientific research results, it was considered that the novel coronary pneumonia has a latent period, so in the later phase of epidemic development, the government has effectively isolated patients, thus we adopt the SEIQR model accordingly. During the period of 2020.3.31-2020.5.16, because more asymptomatic infected people were found, we use the SEIQLR model to fit. Finally, through a SEIR simulator, considering the susceptible number, the latent number, the infected number, the cured number, death number and other factors, we simulate the change of various numbers of people from the beginning to the next 180 days of novel coronary pneumonia. Findings: The results based on the analysis of differential equations and kinetic models show that through the prediction of the model established in the first phase, the epidemic situation of novel coronary pneumonia in Hubei Province was controlled at the end of March, which is in line with the actual situation. The rest of Hubei province, except for Wuhan, lifted control of the departure channel from 0:00 am on March 25, and Wuhan was also unblocked on April 8. Through the establishment of the second-phase model, it is found that the epidemic situation will reach its peak in mid-February. For example, the quarantine admission of the hospital declined after mid-February, which is inseparable from the measures to build square cabin hospitals in early February so that more and more patients can be admitted. The model established in the third phase shows that the epidemic had been completely controlled by the end of May, which is also in line with the reality. Because in mid-May, the Wuhan government conducted a nucleic acid test on all the citizens to screen for asymptomatic infected persons to fundamentally control the spread of novel coronary pneumonia. Interpretation: Hubei Province, as the center of the initial outbreak of novel coronary pneumonia, people were forced to be isolated at home during the Spring Festival, the most important Chinese holiday, and the whole society was in a state of suspension of work and study. The Chinese government had taken many measures in response to the epidemic, such as shutting down the city, vigorously building square cabin hospitals, and prohibiting people from gathering. At the beginning of May this year, the epidemic in Hubei Province was finally effectively controlled. For ordinary citizens, we should not cause unnecessary panic about the unknown novel coronavirus. Instead, we should fully understand and be familiar with this virus. In addition to the relevant medical knowledge, we should also understand the spread of infectious diseases through appropriate mathematical models. By mathematical models, we can understand the degree of harm of infectious diseases, when to control it, how to stop it, and use scientific views to reveal the original face of the novel coronavirus to the public without causing social panic.


2020 ◽  
Vol 5 (3) ◽  
pp. 86-90
Author(s):  
Renata Gerculy ◽  
Camelia Libenciuc ◽  
Nora Rat ◽  
Monica Chitu ◽  
Imre Benedek

AbstractThe novel coronavirus disease first appeared in Wuhan (China) is an infectious disease spreading throughout the world, causing life-threatening conditions in vulnerable or even healthy individuals. The great impact of this virus on healthcare urges physicians to investigate all aspects of the disease in order to overcome its complications. A particularly investigated aspect of the SARS-CoV-2 infection is represented by the coagulation disorders among infected and critically ill patients. Several studies observed modified blood coagulation parameters such as D-dimers, fibrinogen, and coagulation times. Moreover, the severe thrombotic complications, mainly pulmonary embolism, could be responsible for the high mortality and poorer outcomes of COVID-19 infected patients. The aim of this article is to present the current knowledge related to thrombosis predisposition in patients infected with the new coronavirus.


Sign in / Sign up

Export Citation Format

Share Document